Literature DB >> 19669124

A variant in the G6PC2/ABCB11 locus is associated with increased fasting plasma glucose, increased basal hepatic glucose production and increased insulin release after oral and intravenous glucose loads.

C S Rose1, N Grarup, N T Krarup, P Poulsen, L Wegner, T Nielsen, K Banasik, K Faerch, G Andersen, A Albrechtsen, K Borch-Johnsen, J O Clausen, T Jørgensen, A Vaag, O Pedersen, T Hansen.   

Abstract

AIMS/HYPOTHESIS: An association between elevated fasting plasma glucose and the common rs560887 G allele in the G6PC2/ABCB11 locus has been reported. In Danes we aimed to examine rs560887 in relation to plasma glucose and serum insulin responses following oral and i.v. glucose loads and in relation to hepatic glucose production during a hyperinsulinaemic-euglycaemic clamp. Furthermore, we examined rs560887 for association with impaired fasting glycaemia (IFG), impaired glucose tolerance (IGT), type 2 diabetes and components of the metabolic syndrome.
METHODS: rs560887 was genotyped in the Inter99 cohort (n = 5,899), in 366 young, healthy Danes, in non-diabetic relatives of type 2 diabetic patients (n = 196), and in young and elderly twins (n = 159). Participants underwent an OGTT, an IVGTT or a 2 h hyperinsulinaemic-euglycaemic clamp.
RESULTS: The rs560887 G allele associated with elevated fasting plasma glucose (p = 2 x 10(-14)) but not with plasma glucose levels at 30 min (p = 0.9) or 120 min (p = 0.9) during an OGTT. G allele carriers had elevated levels of serum insulin at 30 min during an OGTT (p = 1 x 10(-4)) and relatives of type 2 diabetes patients carrying the G allele had an increased acute insulin response (p = 4 x 10(-4)) during an IVGTT. Among elderly twins, G allele carriers had higher basal hepatic glucose production (p = 0.04). Finally, the G allele associated with the risk of having IFG (OR 1.26, 95% CI 1.08-1.47, p = 0.002), but not with IGT (OR 0.94, 95% CI 0.82-1.08, p = 0.4) or type 2 diabetes (OR 0.93, 95% CI 0.84-1.04, p = 0.2). CONCLUSIONS/
INTERPRETATION: The common rs560887 G allele in the G6PC2/ABCB11 locus is associated with increased fasting glycaemia and increased risk of IFG, associations that may be partly related to an increased basal hepatic glucose production rate.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19669124     DOI: 10.1007/s00125-009-1463-z

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  26 in total

1.  A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: baseline results Inter99.

Authors:  Torben Jørgensen; Knut Borch-Johnsen; Troels F Thomsen; Hans Ibsen; Charlotte Glümer; Charlotta Pisinger
Journal:  Eur J Cardiovasc Prev Rehabil       Date:  2003-10

2.  Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis.

Authors:  P L Jansen; S S Strautnieks; E Jacquemin; M Hadchouel; E M Sokal; G J Hooiveld; J H Koning; A De Jager-Krikken; F Kuipers; F Stellaard; C M Bijleveld; A Gouw; H Van Goor; R J Thompson; M Müller
Journal:  Gastroenterology       Date:  1999-12       Impact factor: 22.682

3.  Cloning and characterization of the human and rat islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP) genes.

Authors:  C C Martin; L J Bischof; B Bergman; L A Hornbuckle; C Hilliker; C Frigeri; D Wahl; C A Svitek; R Wong; J K Goldman; J K Oeser; F Leprêtre; P Froguel; R M O'Brien; J C Hutton
Journal:  J Biol Chem       Date:  2001-04-10       Impact factor: 5.157

4.  Insulin sensitivity index, acute insulin response, and glucose effectiveness in a population-based sample of 380 young healthy Caucasians. Analysis of the impact of gender, body fat, physical fitness, and life-style factors.

Authors:  J O Clausen; K Borch-Johnsen; H Ibsen; R N Bergman; P Hougaard; K Winther; O Pedersen
Journal:  J Clin Invest       Date:  1996-09-01       Impact factor: 14.808

5.  Molecular cloning of a pancreatic islet-specific glucose-6-phosphatase catalytic subunit-related protein.

Authors:  S D Arden; T Zahn; S Steegers; S Webb; B Bergman; R M O'Brien; J C Hutton
Journal:  Diabetes       Date:  1999-03       Impact factor: 9.461

6.  Prevalences of diabetes and impaired glucose regulation in a Danish population: the Inter99 study.

Authors:  Charlotte Glümer; Torben Jørgensen; Knut Borch-Johnsen
Journal:  Diabetes Care       Date:  2003-08       Impact factor: 19.112

7.  Levels of plasma membrane expression in progressive and benign mutations of the bile salt export pump (Bsep/Abcb11) correlate with severity of cholestatic diseases.

Authors:  Ping Lam; Claire L Pearson; Carol J Soroka; Shuhua Xu; Albert Mennone; James L Boyer
Journal:  Am J Physiol Cell Physiol       Date:  2007-09-13       Impact factor: 4.249

8.  Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion.

Authors:  Valeriya Lyssenko; Cecilia L F Nagorny; Michael R Erdos; Nils Wierup; Anna Jonsson; Peter Spégel; Marco Bugliani; Richa Saxena; Malin Fex; Nicolo Pulizzi; Bo Isomaa; Tiinamaija Tuomi; Peter Nilsson; Johanna Kuusisto; Jaakko Tuomilehto; Michael Boehnke; David Altshuler; Frank Sundler; Johan G Eriksson; Anne U Jackson; Markku Laakso; Piero Marchetti; Richard M Watanabe; Hindrik Mulder; Leif Groop
Journal:  Nat Genet       Date:  2008-12-07       Impact factor: 38.330

9.  The islet-specific glucose-6-phosphatase-related protein, implicated in diabetes, is a glycoprotein embedded in the endoplasmic reticulum membrane.

Authors:  Jeng-Jer Shieh; Chi-Jiunn Pan; Brian C Mansfield; Janice Yang Chou
Journal:  FEBS Lett       Date:  2004-03-26       Impact factor: 4.124

10.  A single-nucleotide polymorphism in a methylatable Foxa2 binding site of the G6PC2 promoter is associated with insulin secretion in vivo and increased promoter activity in vitro.

Authors:  Christine Dos Santos; Pierre Bougnères; Delphine Fradin
Journal:  Diabetes       Date:  2008-11-04       Impact factor: 9.461

View more
  17 in total

1.  Detailed physiologic characterization reveals diverse mechanisms for novel genetic Loci regulating glucose and insulin metabolism in humans.

Authors:  Erik Ingelsson; Claudia Langenberg; Marie-France Hivert; Inga Prokopenko; Valeriya Lyssenko; Josée Dupuis; Reedik Mägi; Stephen Sharp; Anne U Jackson; Themistocles L Assimes; Peter Shrader; Joshua W Knowles; Björn Zethelius; Fahim A Abbasi; Richard N Bergman; Antje Bergmann; Christian Berne; Michael Boehnke; Lori L Bonnycastle; Stefan R Bornstein; Thomas A Buchanan; Suzannah J Bumpstead; Yvonne Böttcher; Peter Chines; Francis S Collins; Cyrus C Cooper; Elaine M Dennison; Michael R Erdos; Ele Ferrannini; Caroline S Fox; Jürgen Graessler; Ke Hao; Bo Isomaa; Karen A Jameson; Peter Kovacs; Johanna Kuusisto; Markku Laakso; Claes Ladenvall; Karen L Mohlke; Mario A Morken; Narisu Narisu; David M Nathan; Laura Pascoe; Felicity Payne; John R Petrie; Avan A Sayer; Peter E H Schwarz; Laura J Scott; Heather M Stringham; Michael Stumvoll; Amy J Swift; Ann-Christine Syvänen; Tiinamaija Tuomi; Jaakko Tuomilehto; Anke Tönjes; Timo T Valle; Gordon H Williams; Lars Lind; Inês Barroso; Thomas Quertermous; Mark Walker; Nicholas J Wareham; James B Meigs; Mark I McCarthy; Leif Groop; Richard M Watanabe; Jose C Florez
Journal:  Diabetes       Date:  2010-02-25       Impact factor: 9.461

2.  JASS: command line and web interface for the joint analysis of GWAS results.

Authors:  Hanna Julienne; Pierre Lechat; Vincent Guillemot; Carla Lasry; Chunzi Yao; Robinson Araud; Vincent Laville; Bjarni Vilhjalmsson; Hervé Ménager; Hugues Aschard
Journal:  NAR Genom Bioinform       Date:  2020-01-24

3.  Genetic variation at glucose and insulin trait loci and response to glucose-insulin-potassium (GIK) therapy: the IMMEDIATE trial.

Authors:  K L Ellis; Y Zhou; J R Beshansky; E Ainehsazan; Y Yang; H P Selker; G S Huggins; L A Cupples; I Peter
Journal:  Pharmacogenomics J       Date:  2014-08-19       Impact factor: 3.550

4.  Effects of G6pc2 deletion on body weight and cholesterol in mice.

Authors:  Kayla A Boortz; Kristen E Syring; Lynley D Pound; Huan Mo; Lisa Bastarache; James K Oeser; Owen P McGuinness; Joshua C Denny; Richard M O'Brien
Journal:  J Mol Endocrinol       Date:  2017-01-25       Impact factor: 5.098

5.  Variants at DGKB/TMEM195, ADRA2A, GLIS3 and C2CD4B loci are associated with reduced glucose-stimulated beta cell function in middle-aged Danish people.

Authors:  T W Boesgaard; N Grarup; T Jørgensen; K Borch-Johnsen; T Hansen; O Pedersen
Journal:  Diabetologia       Date:  2010-04-26       Impact factor: 10.122

6.  Common polymorphisms in MTNR1B, G6PC2 and GCK are associated with increased fasting plasma glucose and impaired beta-cell function in Chinese subjects.

Authors:  Claudia Ha Ting Tam; Janice Sin Ka Ho; Ying Wang; Heung Man Lee; Vincent Kwok Lim Lam; Soren Germer; Mitchell Martin; Wing Yee So; Ronald Ching Wan Ma; Juliana Chung Ngor Chan; Maggie Chor Yin Ng
Journal:  PLoS One       Date:  2010-07-08       Impact factor: 3.240

Review 7.  Physiologic characterization of type 2 diabetes-related loci.

Authors:  Niels Grarup; Thomas Sparsø; Torben Hansen
Journal:  Curr Diab Rep       Date:  2010-12       Impact factor: 4.810

8.  G6PC2 Modulates the Effects of Dexamethasone on Fasting Blood Glucose and Glucose Tolerance.

Authors:  Kayla A Boortz; Kristen E Syring; Rebecca A Lee; Chunhua Dai; James K Oeser; Owen P McGuinness; Jen-Chywan Wang; Richard M O'Brien
Journal:  Endocrinology       Date:  2016-09-21       Impact factor: 4.736

9.  Moving on from GWAS: functional studies on the G6PC2 gene implicated in the regulation of fasting blood glucose.

Authors:  Richard M O'Brien
Journal:  Curr Diab Rep       Date:  2013-12       Impact factor: 4.810

10.  Effects of genetic variants previously associated with fasting glucose and insulin in the Diabetes Prevention Program.

Authors:  Jose C Florez; Kathleen A Jablonski; Jarred B McAteer; Paul W Franks; Clinton C Mason; Kieren Mather; Edward Horton; Ronald Goldberg; Dana Dabelea; Steven E Kahn; Richard F Arakaki; Alan R Shuldiner; William C Knowler
Journal:  PLoS One       Date:  2012-09-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.